Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
SAB Biotherapeutics

SAB Biotherapeutics

SAB Biotherapeutics is a therapeutics and immunotherapy research and development company based in Sioux Falls, South Dakota.

SAB Biotherapeutics is a therapeutics and immunotherapy research and development company. SAB Biotherapeutics, Inc. is a company that is involved in R&D, it is using the advancement of science and genius of nature to transform the landscape of human health. It consists of a team of scientists, researchers and professionals that use technology and tenacity to pioneer a new powerful platform for making global and personal impact.

Through the use of an advanced genetic engineering and antibody science, it is dedicated to advancing a new class of immunotherapies, by leveraging the native human immune response, with first-in-class and best-in-class potential across wide therapeutic categories that include autoimmune, inflammation, infectious disease and immune-oncology. SAB-185, is among the elite therapy candidates for COVID-19, advancing with Operation Warp Speed.

As a true innovation, its novel platform is also being developed in a rapid response capacity for future response to pandemics.

Timeline

July 17, 2020
SAB Biotherapeutics raises a $14,000,000 series B round.
April 16, 2020
SAB Biotherapeutics (SAB) announced today that it has been awarded expanded scope on their Rapid Response contract for their new therapeutic drug candidate to treat COVID-19, from the Department of Defense (DoD)
April 8, 2020
CSL Behring and human antibody development company SAB Biotherapeutics (SAB) announced their partnership to combat the coronavirus pandemic with the rapid development of SAB-185, a COVID-19 therapeutic candidate on track for clinical evaluation by early summer.

CSL Behring has provided seed funding to offset some initial development costs that were funded by SAB in good faith, responding to the global pandemic as quickly as possible.

2014
SAB Biotherapeutics was founded by Eddie Sullivan and Edward Hamilton.

Funding Rounds

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Annalee Armstrong
September 22, 2021
FierceBiotech
SAB Biotherapeutics has snared another $60.5 million from the U.S. Department of Defense to fund an antibody program to treat COVID-19. This brings the total funding SAB's received from the Biomedical Advanced Research Development Authority and the DoD to $200 million.
Brandon May
June 22, 2021
BioSpace
The business combination agreement will advance SAB's proprietary platform to develop antibody therapies for immune system disorders and other diseases.
Amirah Al Idrus
June 22, 2021
FierceBiotech
After grabbing government grants to develop its polyclonal antibody treatment for COVID-19, SAB Biotherapeutics is going public through a $118 million SPAC merger. The proceeds will bankroll a pipeline of treatments for various diseases that are produced by and extracted from genetically modified cows.
BioSpace
June 10, 2021
BioSpace
SAB Biotherapeutics (SAB), today announced the appointment of Carlos Carrillo, PhD, as senior vice president, regulatory affairs.
BioSpace
April 13, 2021
BioSpace
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies, today announced that Kipp Erickson, PhD, has joined the company as Chief Operating Officer (COO).
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.